Viridian Therapeutics Inc
Research Viridian Therapeutics Inc (VRDN) on Bullrun: market cap USD 2.74B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVRDN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.74B
- Financial periodQ2 2026
- RevenueUSD 284.00K
- Net income-USD 127.12M
- Free cash flow-USD 106.63M
Valuation Snapshot
latest market cap is USD 2.74B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 70.85M | -USD 342.60M | -USD 276.89M | n/a | -3.29 | USD 212.38M | USD 50.69M | USD 722.17M |
| FY2024 | USD 302.00K | -USD 269.90M | -USD 232.83M | n/a | -3.05 | USD 99.59M | USD 20.58M | USD 671.64M |
| FY2023 | USD 314.00K | -USD 237.70M | -USD 185.07M | n/a | -5.31 | USD 102.83M | USD 20.21M | USD 442.02M |
| FY2022 | USD 1.77M | -USD 129.90M | -USD 94.64M | n/a | -4.05 | USD 155.58M | USD 4.65M | USD 395.06M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.74B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.17B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.55B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.15B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.18B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 472.98M | n/a | n/a | n/a |
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Viridian Therapeutics Inc's market cap?
Viridian Therapeutics Inc's market capitalization is USD 2.74B.
What does Viridian Therapeutics Inc do?
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED.